Aytu Biopharma (AYTU) Gross Profit (2014 - 2026)

Aytu Biopharma (AYTU) has reported Gross Profit for 13 consecutive years, with $7.6 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Gross Profit fell 40.66% year-over-year to $7.6 million in Q1 2026; TTM through Mar 2026 was $36.7 million, a 21.37% decrease from a year earlier, with the FY2025 full-year figure at $45.8 million, down 6.57% from the prior year.
• Gross Profit was $7.6 million for Q1 2026 at Aytu Biopharma, down from $9.6 million in the prior quarter.
• Over five years, Gross Profit peaked at $18.6 million in Q2 2023 and troughed at $7.6 million in Q1 2026.
• A 5-year average of $12.7 million and a median of $12.7 million in 2022 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit jumped 44.77% in 2022 and slumped 40.66% in 2026, its largest moves.
• Over 5 years, Gross Profit stood at $17.3 million in 2022, then slipped by 15.56% to $14.6 million in 2023, then dropped by 26.14% to $10.8 million in 2024, then dropped by 10.77% to $9.6 million in 2025, then retreated by 21.04% to $7.6 million in 2026.
• The last three Gross Profit figures came in at $7.6 million (Q1 2026), $9.6 million (Q4 2025), and $9.2 million (Q3 2025), per Business Quant data.